Preoperative serum prostate-specific antigen, clinical stage and Gleason sum as basis for predicting final pathological stage in Japanese patients with prostate cancer

Japanese Journal of Clinical Oncology

Volumn 26, Issue 6, 1996, Pages 438-444

  Egawa, Shin ^a   Koh, Hideshige ^a   Satoh, Takefumi ^a   Ohori, Makoto ^a   Uchida, Toyoaki ^a   Kuwao, Sadahito ^a   Koshiba, Ken ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical staging; Pathological stage; Prostate cancer; Prostate specific antigen; Tumor grade

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; BLOOD; CANCER STAGING; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REGRESSION ANALYSIS;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 0030331769     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023261     Document Type: Article

References (26)

1. Kakizoe T: Figures on Cancer in Japan-1995, Foundation for Promotion of Cancer Research, Tokyo. p34-35, 1995 (in Japanese)
2. Tominaga S, Aoki K, Hanai A, Kurihara N: Cancer Statistics-Incidence/Mortality/Prognosis, 1993, Shinohara Publishing Co., Tokyo. p154-170, 1993 (in Japanese)
3. Statistics and Information Department: Vital Statistics 1995 Japan, Minister's Secretariat, Ministry of Health and Welfare 3: 100-101, 1995 (in Japanese)
4. Catalona WJ, Bigg SW: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143: 538-544, 1990
5. deKernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 144: 700-703, 1990
6. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, Lo R, Palmer K, Shinohara K, Spaulding JT: The role of transrectal ultrasoundguided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 46: 205-212, 1995
7. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993
8. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151: 1315-1320, 1994
9. Egawa S, Suyama K, Ohori M, Kawakami T, Kuwao S, Hirokado K, Hirano S, Yokoyama E, Uchida T, Koshiba K: Early detection of prostate cancer: results of a prostate specific antigen-based detection program in Japan. Cancer 76: 463-472, 1995
10. International Union Against Cancer: TNM Atlas, 3rd ed, 2nd revision 1992, Springer-Verlag, New York. p241-250, 1992
11. Klee GG, Dodge LA, Zincke H, Oesterling JE: Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol 151: 94-98, 1994
12. Machida T, Ohishi Y, Wada T, Akimoto S, Shimazaki J, Oda H, Yokoyama M, Tsukada T, Nakayama T, Akiyama A, Miki M, Meguro N, Usami M, Kotake T, Yamamoto M, Naito K: Clinical evaluation of a new kit(IMx PA Dinapak® for detection of serum prostate specific antigen. Hinyokika Kiyo 39: 977-984, 1993 (in Japanese)
13. Ogawa Y, Morikawa J, Ohsawa R, Machida T, Miki M, Yanagisawa M: Purification and determination of human prostate specific antigen in the serum. Radioisotopes 33: 273-278, 1984 (in Japanese)
14. Hodge KK, McNeal JE, Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142: 66-70, 1989
15. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146: 1069-1076, 1991
16. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845-1850, 1993
17. Oesterling JE, Suman VJ, Zincke H, Bostwick DG: PSA-detected(clinical stage Tie or BO) prostate cancer: pathologically significant tumors. Urol Clin North Am 20: 687-693, 1993
18. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, Jacobsen SJ, Lieber MM: Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 75: 347-353, 1995
19. Brawer MK, Wener MH, Daum PR, Close B: Method to method variation in assays for prostate specific antigen (Abstr). J Urol 151: 450A, 1994
20. Jacobsen SJ, Wright GL Jr, Lilja H, Pettersson K, Klee GG, Oesterling JE: Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology 44: 512-518, 1994
21. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887-889, 1992
22. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990
23. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI: Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. J Urol 154: 1808-1812, 1995
24. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993
25. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J: Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 154: 1085-1089, 1995
26. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995